Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
JAMA Oncology
|
January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer
Dawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Journal for Immunotherapy of Cancer
|
July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)
Sandip P Patel, Megan Othus, Young K Chae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702
Seohyuk Lee, Chao Ma, Qian Shi, et al.
Cancer
|
August 10, 2021
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)
Rebecca A Snyder, Jun He, Jennifer Le-Rademacher, et al.
Clinical Colorectal Cancer
|
January 1, 2017
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)
Tamás Pinter, Zandra Klippel, Alvydas Cesas, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
Young Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J Wagner, Megan Othus, Sandip P Patel, et al.
JAMA
|
April 6, 2021
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial
Jeffrey A Meyerhardt, Qian Shi, Charles S Fuchs, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
JAMA Oncology
|
January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer
Dawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Journal for Immunotherapy of Cancer
|
July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)
Sandip P Patel, Megan Othus, Young K Chae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702
Seohyuk Lee, Chao Ma, Qian Shi, et al.
Cancer
|
August 10, 2021
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)
Rebecca A Snyder, Jun He, Jennifer Le-Rademacher, et al.
Clinical Colorectal Cancer
|
January 1, 2017
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)
Tamás Pinter, Zandra Klippel, Alvydas Cesas, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
Young Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J Wagner, Megan Othus, Sandip P Patel, et al.
JAMA
|
April 6, 2021
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial
Jeffrey A Meyerhardt, Qian Shi, Charles S Fuchs, et al.
Page
of 4